Last reviewed · How we verify

Topiramate-Implant — Competitive Intelligence Brief

Topiramate-Implant (Topiramate-Implant) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant / Antiepileptic agent. Area: Neurology.

marketed Anticonvulsant / Antiepileptic agent GABA-A receptor, sodium channels, glutamate receptors Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Topiramate-Implant (Topiramate-Implant) — University of Sao Paulo. Topiramate is a sulfamate-substituted monosaccharide that enhances GABA-mediated inhibition and blocks sodium channels to reduce neuronal excitability.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Topiramate-Implant TARGET Topiramate-Implant University of Sao Paulo marketed Anticonvulsant / Antiepileptic agent GABA-A receptor, sodium channels, glutamate receptors
Topiramate monotherapy Topiramate monotherapy Johnson & Johnson Taiwan Ltd marketed Anticonvulsant / Antiepileptic agent GABA-A receptor; voltage-gated sodium channels
zonisamide low dose group zonisamide low dose group Eisai Korea Inc. marketed Anticonvulsant / Antiepileptic agent Sodium channels, calcium channels, carbonic anhydrase
Standard dose topiramate Standard dose topiramate Mario Negri Institute for Pharmacological Research marketed Anticonvulsant / Antiepileptic agent Voltage-gated sodium channels, GABA-A receptors, carbonic anhydrase
Topiramate Standard Topiramate Standard Janssen Korea, Ltd., Korea marketed Anticonvulsant / Antiepileptic agent Voltage-gated sodium channels, GABA-A receptors, carbonic anhydrase
Carbamazepine-Implant Carbamazepine-Implant University of Sao Paulo marketed Anticonvulsant / Antiepileptic agent Voltage-gated sodium channels
carbamazepine oxcarbazepine carbamazepine oxcarbazepine Odense University Hospital marketed Anticonvulsant / Antiepileptic agent Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant / Antiepileptic agent class)

  1. University of Sao Paulo · 2 drugs in this class
  2. Mario Negri Institute for Pharmacological Research · 2 drugs in this class
  3. Janssen Korea, Ltd., Korea · 1 drug in this class
  4. Johnson & Johnson Taiwan Ltd · 1 drug in this class
  5. Ministry of Health and Sports, Myanmar · 1 drug in this class
  6. Odense University Hospital · 1 drug in this class
  7. UCB BIOSCIENCES GmbH · 1 drug in this class
  8. University Hospitals Cleveland Medical Center · 1 drug in this class
  9. Eisai Korea Inc. · 1 drug in this class
  10. Upsher-Smith Laboratories · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Topiramate-Implant — Competitive Intelligence Brief. https://druglandscape.com/ci/topiramate-implant. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: